+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Dose escalation study with two different hypofractionated intensity modulated radiotherapy techniques for localized prostate cancer: acute toxicity



Dose escalation study with two different hypofractionated intensity modulated radiotherapy techniques for localized prostate cancer: acute toxicity



Technology in Cancer Research and Treatment 9(3): 263-270



To assess acute gastrointestinal (GI) and genitourinary (GU) toxicities in patients with localized prostate cancer treated with a sequential dose escalation hypofractionated intensity-modulated radiotherapy (IMRT) study using two different delivery methods. Since 2003, 88 and 48 patients were sequentially treated to 56 Gy and to 60 Gy (4 Gy/fraction twice weekly), respectively. IMRT with 6 MV beams was delivered with five fields in Geneva and with nine in Barcelona. Acute GI and GU side effects were scored weekly during treatment and 6 weeks after treatment completion using the Radiation Therapy Oncology Group (RTOG) toxicity scale. Clinical, technical, and dosimetric parameters were analyzed in order to assess for a potential correlation with toxicity. Grade 1-2, GU and GI toxicities during and 6 weeks after treatment completion were 64%, and 24%, and 35% and 12%, respectively. Only one Grade 4 GU toxicity, consisting of transitory urinary obstruction, was observed. Patients treated to 60 Gy in Geneva presented a higher rate of Grade 1-2 GU toxicity (p = 0.01), while patients treated to both 56 and 60 Gy in Barcelona presented a higher Grade 1-2 GI toxicity (p = 0.02). A lower rate of rectal toxicity was observed in the subgroup of 22 patients treated with a rectal balloon (p = 0.02). The use of androgen deprivation therapy was associated with a higher rate of Grade 1-2 GU toxicity after the end of the treatment (p = 0.02). Dose escalation with either 14 _ 4 Gy or 15 _ 4 Gy delivered with two different IMRT techniques is feasible and is associated with a tolerable acute toxicity.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052703620

Download citation: RISBibTeXText

PMID: 20441236

DOI: 10.1177/153303461000900305


Related references

Twice-weekly hypofractionated intensity-modulated radiotherapy for localized prostate cancer with low-risk nodal involvement: toxicity and outcome from a dose escalation pilot study. International Journal of Radiation Oncology Biology Physics 81(2): 382-389, 2011

Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. International Journal of Radiation Oncology Biology Physics 73(3): 685-691, 2009

Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results. International Journal of Radiation Oncology, Biology, Physics 72(1): 85-92, 2008

A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy. International Journal of Radiation Oncology Biology Physics 82(4): E657-E662, 2012

Poster The Hipro (Hypofractionated Dose Escalation Utilising Intensity Modulated Radiotherapy in Carcinoma of the Prostate) Study Late Toxicity and Outcome at 7 Years. European Journal of Cancer 47: S495-S496, 2011

Localised prostate cancer new surgical and radiation techniques: Radical radiotherapy Techniques, results and side effects (evolving tools in definitive radiotherapy, intensity modulated radiotherapy, image guided radiotherapy and their role in dose escalation). European Journal of Cancer Suppl.s 5(5): 400-401, 2007

Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study. International Journal of Radiation Oncology Biology Physics 78(1): 50-57, 2010

Acute toxicity of hypofractionated intensity-modulated radiotherapy for prostate cancer. Current Oncology 22(2): E76-E84, 2015

Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. International Journal of Radiation Oncology Biology Physics 72(3): 799-807, 2008

The rationale behind hypofractionated high-dose intensity-modulated radiotherapy in patients with localized prostate cancer: short review. Annales Academiae Medicae Stetinensis 58(1): 45-48, 2012

Dose escalation using a hypofractionated, intensity-modulated radiation therapy boost for localized prostate cancer: preliminary results addressing concerns of high or low alpha/beta ratio. Clinical Genitourinary Cancer 7(3): E52-E57, 2009

Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy. Cancer 115(23): 5596-5606, 2009

Outcome and patient-reported toxicity in localised prostate cancer treated with dose-escalated hypofractionated intensity-modulated radiotherapy. Journal of RadioTherapy in Practice 12(04): 326-333, 2013

Hypofractionated intensity-modulated radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics 57(2 Suppl.): S275-S276, 2003

Conformal radiotherapy versus short-course intensity modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland Dosimetry and acute toxicity. International Journal of Radiation Oncology Biology Physics 45(3 Suppl. ): 264, 1999